Allarity Therapeutics, Inc. (ALLR) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Allarity Therapeutics reported revenue of $320,000. Net income was -$11.2M (a -3509.7% net margin). Operating margin was -3939.1%. Operating activities generated -$14.8M of cash, leaving -$14.8M of free cash flow. At fiscal year end, Allarity Therapeutics held $18.3M in total assets against $8.4M in total liabilities, including $14.7M of cash and equivalents.
Open the full interactive Allarity Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Allarity Therapeutics Key Stats
| Share Price | $0.87 |
|---|---|
| Market Cap | $13.8M |
| 52-Week Range | $0.81 – $1.77 |
| Shares Outstanding | 15.9 million (basic, 2026 Q2) |
Allarity Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $320,000 |
| Operating Income | -$26.6M | -$34.5M | -$17.1M | -$27.2M | -$12.6M |
| Pre-Tax Income | -$26.5M | -$17.6M | -$11.8M | -$24.9M | -$11.2M |
| Income Tax | $133,000 | -$1.5M | $83,000 | -$381,000 | $0 |
| Net Income | -$26.6M | -$16.1M | -$11.9M | -$24.5M | -$11.2M |
| Diluted EPS | -$3520107.29 | -$1856400.00 | -$6156.00 | — | — |
Allarity Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $320,000 | $25,000 | $0 |
| Net Income | -$2.8M | -$3.4M | -$2.8M | -$3.4M |
Allarity Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | — | — | $166,000 | $19.5M | $14.7M |
| Current Assets | $21.1M | $5.0M | $2.0M | $22.3M | $17.9M |
| Total Assets | $49.6M | $14.5M | $11.9M | $22.6M | $18.3M |
| Current Liabilities | $20.7M | $11.2M | $14.2M | $10.8M | $8.4M |
| Total Long-Term Debt | $1.1M | $2.6M | — | — | — |
| Total Liabilities | $30.8M | $12.7M | $14.6M | $10.8M | $8.4M |
| Shareholders' Equity | $18.2M | -$113,000 | -$2.8M | $11.8M | $9.8M |
Allarity Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$15.1M | -$16.8M | -$12.7M | -$17.4M | -$14.8M |
| Cash From Investing | $1.0M | $791,000 | — | -$298,000 | -$8,000 |
| Cash From Financing | $33.8M | -$1.3M | $11.0M | $36.8M | $10.6M |
| Free Cash Flow | -$15.1M | -$16.8M | -$12.8M | -$17.6M | -$14.8M |
Figures from Allarity Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Allarity Therapeutics financials page for every line item.
Allarity Therapeutics Company Profile
| Ticker | ALLR |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001860657 |
Frequently Asked Questions
What was Allarity Therapeutics' revenue in fiscal 2025?
Allarity Therapeutics (ALLR) reported revenue of $320,000 for fiscal 2025.
What is Allarity Therapeutics' annual revenue history?
Allarity Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $320,000.
What was Allarity Therapeutics' net income in fiscal 2025?
Allarity Therapeutics reported net income of -$11.2M for fiscal 2025.
How much free cash flow did Allarity Therapeutics generate in fiscal 2025?
Allarity Therapeutics generated -$14.8M of free cash flow in fiscal 2025.
What was Allarity Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Allarity Therapeutics reported revenue of $0.
How many shares of Allarity Therapeutics are outstanding?
Allarity Therapeutics reported a weighted average of 15.9 million basic shares outstanding in 2026 Q2.
What is Allarity Therapeutics' market cap?
Based on its latest closing price, Allarity Therapeutics (ALLR) has a market capitalization of about $13.8M.
When does Allarity Therapeutics' fiscal year end?
Allarity Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Allarity Therapeutics headquartered?
Allarity Therapeutics lists its business address in Boston, Massachusetts in its SEC filings.